Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

513 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia.
Wakita S, Sakaguchi M, Oh I, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Tajika K, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Kayamori K, Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S, Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Marumo A, Omori I, Fujiwara Y, Terada K, Yui S, Arai K, Kitano T, Miyata M, Kurosawa A, Mizoguchi A, Komatsu N, Fukuda T, Ohashi K, Kanda Y, Inokuchi K, Yamaguchi H. Wakita S, et al. Among authors: ando j. Blood Adv. 2022 Jan 11;6(1):238-247. doi: 10.1182/bloodadvances.2021004292. Blood Adv. 2022. PMID: 34448807 Free PMC article.
NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia.
Marumo A, Wakita S, Morita K, Oh I, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Uoshima N, Kobayashi Y, Kawata E, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Hagihara M, Uchiyama H, Kubota Y, Kimura S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Date K, Fujiwara Y, Terada K, Yui S, Arai K, Kitano T, Miyata M, Ohashi K, Kanda Y, Yamaguchi H. Marumo A, et al. Among authors: ando j. Int J Hematol. 2022 Aug;116(2):199-214. doi: 10.1007/s12185-022-03328-6. Epub 2022 Apr 4. Int J Hematol. 2022. PMID: 35377134
Primary Lymphoma of the Pericardium.
Kinoshita S, Ando J, Ando M, Komatsu N. Kinoshita S, et al. Among authors: ando j, ando m. Intern Med. 2021 Dec 15;60(24):4005-4006. doi: 10.2169/internalmedicine.7643-21. Epub 2021 Jun 12. Intern Med. 2021. PMID: 34121016 Free PMC article. No abstract available.
Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy.
Yoshida C, Kondo T, Ito T, Kizaki M, Yamamoto K, Miyamoto T, Morita Y, Eto T, Katsuoka Y, Takezako N, Uoshima N, Imada K, Ando J, Komeno T, Mori A, Ishikawa Y, Satake A, Watanabe J, Kawakami Y, Morita T, Taneike I, Nakayama M, Duan Y, Garbayo Guijarro B, Delgado A, Llamas C, Kiyoi H. Yoshida C, et al. Among authors: ando j. Int J Hematol. 2022 Jul;116(1):89-101. doi: 10.1007/s12185-022-03334-8. Epub 2022 Apr 8. Int J Hematol. 2022. PMID: 35394258
Diffuse Large B-cell Lymphoma with Adrenal Involvement Presenting as Other Iatrogenic Immunodeficiency-associated Lymphoproliferative Disorders: Sustained Remission with Methotrexate Termination Alone in Two Cases.
Yasuda H, Ando J, Yoshida S, Ota Y, Komatsu N, Ando M. Yasuda H, et al. Among authors: ando j, ando m. Intern Med. 2023 Feb 15;62(4):601-604. doi: 10.2169/internalmedicine.0130-22. Epub 2022 Jul 5. Intern Med. 2023. PMID: 35793959 Free PMC article.
513 results